Iptacopan hydrochloride - Generic Drug Details

What are the generic sources for iptacopan hydrochloride and what is the scope of freedom to operate?

Iptacopan hydrochloride is the generic ingredient in one branded drug marketed by Novartis and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Iptacopan hydrochloride has one hundred and ten patent family members in forty-three countries.

One supplier is listed for this compound.

Summary for iptacopan hydrochloride

International Patents:	110
US Patents:	8
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	19
Patent Applications:	18
DailyMed Link:	iptacopan hydrochloride at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for iptacopan hydrochloride

Constraining patent/regulatory exclusivity:

TREATMENT OF ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for iptacopan hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Bing Han	NA
Novartis Pharmaceuticals	PHASE2
Novartis Pharmaceuticals	PHASE3

See all iptacopan hydrochloride clinical trials

Pharmacology for iptacopan hydrochloride

Drug Class	Complement Factor B Inhibitor
Mechanism of Action	Complement Factor B Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for iptacopan hydrochloride

L04AJ	Complement inhibitors
L04A	IMMUNOSUPPRESSANTS
L04	IMMUNOSUPPRESSANTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for iptacopan hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	FABHALTA	iptacopan hydrochloride	CAPSULE;ORAL	218276-001	Dec 5, 2023		RX	Yes	Yes
Novartis	FABHALTA	iptacopan hydrochloride	CAPSULE;ORAL	218276-001	Dec 5, 2023		RX	Yes	Yes
Novartis	FABHALTA	iptacopan hydrochloride	CAPSULE;ORAL	218276-001	Dec 5, 2023		RX	Yes	Yes	10,093,663

International Patents for iptacopan hydrochloride

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2021234544
Singapore	11201600086P	PIPERIDINYL INDOLE DERIVATIVES AND THEIR USE AS COMPLEMENT FACTOR B INHIBITORS
China	117338781	哌啶基-吲哚衍生物的用途 (Application of piperidinyl-indole derivative)

Supplementary Protection Certificates for iptacopan hydrochloride

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3022192	24C1036	France		PRODUCT NAME: IPTACOPAN OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/24/1802 20240521
3022192	C202430039	Spain		PRODUCT NAME: IPTACOPAN O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/24/1802; DATE OF AUTHORISATION: 20240517; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/24/1802; DATE OF FIRST AUTHORISATION IN EEA: 20240517
3022192	LUC00358	Luxembourg		PRODUCT NAME: IPTACOPAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/24/1802 20240521

Market Dynamics and Financial Trajectory for IPTACOPAN HYDROCHLORIDE

Last updated: July 27, 2025

Introduction

Ipacopan Hydrochloride, a potent inhibitor targeting the complement system component factor B, has garnered attention for its therapeutic potential in rare and severe diseases such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and geographic atrophy associated with age-related macular degeneration (AMD). As the pharmaceutical landscape evolves, understanding the market dynamics and forecasting its financial trajectory are critical for stakeholders, including investors, healthcare providers, and pharmaceutical companies.

Pharmacological Profile and Therapeutic Indications

Ipacopan (also known as LNP023) innovatively targets the complement alternative pathway, a crucial component in immune regulation and inflammatory processes. Its mechanism involves selective inhibition of factor B, thereby suppressing pathological complement activation while preserving host defense mechanisms.

Initial clinical studies focus on:

• PNH: Addressing hemolytic episodes linked to complement dysregulation.
• aHUS: Treating thrombotic microangiopathy resulting from complement overactivation.
• Dry AMD with geographic atrophy: Slowing progressive vision loss linked to complement-mediated retinal damage.

Market potential hinges on both orphan disease approval pathways and expansion into broader indications, emphasizing its high-value therapeutic niche.

Market Dynamics

1. Competitive Landscape

Ipacopan faces competition from existing complement inhibitors like eculizumab (Soliris) and ravulizumab (Ultomiris), primarily directed at PNH and aHUS. However, these agents, while effective, are marred by high costs, inconvenient administration schedules, and notable adverse events (e.g., increased infection risk).

Ipacopan’s oral formulation confers a competitive advantage over intravenous therapies, potentially improving patient adherence and reducing healthcare system burden. Moreover, ongoing trials explore its efficacy in additional indications, including geographic atrophy, which lacks approved treatments, elevating its market appeal.

2. Regulatory and Reimbursement Climate

Regulatory agencies such as the U.S. FDA and EMA have shown openness to expedited pathways like breakthrough therapy designations for drugs showing significant clinical benefit. Pending or granted orphan status further accelerates approval timelines.

Reimbursement strategies will be shaped by demonstrated clinical superiority, safety profiles, and cost-effectiveness analyses. Payers are increasingly scrutinizing high-cost biologics, favoring oral small-molecule alternatives if proven efficacious.

3. Market Penetration and Adoption

Early-phase clinical success suggests rapid uptake among specialists managing PNH and aHUS, especially if superior safety profiles are confirmed. As more data supports its efficacy in geographic atrophy, broader ophthalmology markets may open, expanding its footprint significantly.

Physician acceptance hinges on balancing efficacy, cost, and administration convenience. Patient advocacy groups and educational initiatives will influence adoption trajectories.

Financial Trajectory

1. Revenue Projections

Given current data, initial revenues are expected to stem from PNH and aHUS indications, with potential multibillion-dollar global sales given the unmet needs and market size:

• PNH & aHUS Markets: The combined global market value exceeds $5 billion, considering the patient populations are estimated at approximately 7,000 and 2,000 patients, respectively, in the U.S. alone [1][2].

• Geographic Atrophy Expansion: Market estimates for AMD with geographic atrophy could reach $10 billion worldwide, driven by the prevalence of AMD (approximately 196 million globally) [3].

Based on clinical trial success, first commercial revenue could materialize within 2-3 years post-approval, scaling upward as indications expand and market penetration deepens.

2. Cost Structure and Investment

Significant investments underpin clinical trials, regulatory submission, manufacturing, and commercialization. R&D expenditure for IPACOPAN is projected to exceed $300 million pre-launch, with manufacturing costs decreasing over time due to scale economies.

Margins are expected to improve as production stabilizes, and market share increases, particularly if the drug shifts the treatment paradigm from biologics to oral therapy.

3. Growth Drivers and Risks

Key growth factors include:

• Regulatory approvals in multiple jurisdictions.
• Market access via favorable reimbursement policies.
• Enhanced clinical data demonstrating superiority or additional indications.

Risks involve:

• Delayed approvals or clinical setbacks.
• Pricing pressures from payers.
• Competition from emerging therapies (e.g., gene therapies, other complement inhibitors).

Strategic Outlook

Future growth hinges on successful clinical trials, navigating regulatory pathways, and strategic alliances. Licensing agreements and partnerships with ophthalmology and hematology specialists can facilitate market entry and accelerate revenue streams.

Adoption of digital health tools for monitoring treatment adherence could further optimize financial outcomes and patient engagement.

Conclusion

Ipacopan Hydrochloride stands at a confluence of innovation and unmet medical need, with promising market dynamics driven by its unique mechanism, oral formulation, and strategic clinical positioning. While initial revenue streams may be concentrated within niche, high-value markets, the drug's long-term financial potential hinges on expanding indications, ensuring regulatory success, and navigating evolving payer landscapes.

---

Key Takeaways

• Ipacopan’s targeted inhibition of factor B offers a competitive edge over existing biologics, especially with oral administration.
• Market potential is substantial, particularly if approved for AMD with geographic atrophy, a large, underserved condition.
• Early clinical success and favorable safety profiles are pivotal for rapid adoption and revenue growth.
• Regulatory support and reimbursement strategies will significantly influence its financial trajectory.
• Strategic partnerships and expanding indications will be essential for maximizing market penetration and profitability.

---

FAQs

1. What differentiates Ipacopan from existing complement inhibitors?
Unlike biologic agents such as eculizumab, Ipacopan is an oral small molecule, offering convenience, reduced administration costs, and potentially improved patient adherence.

2. Which indications are most promising for Ipacopan in the near term?
Paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) are the primary near-term indications given existing clinical trial data and regulatory pathways.

3. What are the main challenges facing Ipacopan’s market entry?
Key challenges include navigating regulatory approvals, demonstrating cost-effectiveness for payers, and competing with established biologics.

4. How could expanding into AMD impact the drug's market size?
Approval for geographic atrophy associated with dry AMD could unlock a multibillion-dollar market, as current treatments are limited or nonexistent, significantly elevating sales potential.

5. What strategies can pharmaceutical companies employ to maximize Ipacopan’s commercial success?
Forming strategic alliances, investing in robust clinical development, engaging with patient advocacy groups, and ensuring favorable reimbursement terms can facilitate market penetration and revenue growth.

---

References

[1] U.S. Food and Drug Administration, “Orphan Drug Designations,” 2022.
[2] GlobalData, “Market Analysis for Hematologic Disorders,” 2022.
[3] Wong, W., et al. “Global prevalence of age-related macular degeneration,” Eye, 2014.